24 Hrs
Source:
الاقتصادية
Pharmaceutical firms rely on Chinese licenses
The article discusses China's growing role in drug development, especially in cancer treatment, where it has become a center of pharmaceutical innovation with expanding partnerships with American pharmaceutical companies. Over the course of this year, Western and Chinese companies have signed more than 32 licensing deals, with expectations to surpass 45 deals by 2026, as collaboration continues in advanced clinical trials for drugs developed by both sides, including treatments for cancer and obesity. However, this cooperation faces concerns over China's potential dominance and its impact on U.S. leadership, as Congress seeks to impose restrictions on these deals. American companies are still trying to strike a balance between benefiting from Chinese innovations and protecting their interests and technological standing. Despite the risks, the collaboration persists, as Chinese and American companies depend on each other, with deal activity and partnership expansion in the pharmaceutical sector continuing steadily.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)